Loren Data's SAM Daily™

FBO DAILY ISSUE OF APRIL 03, 2004 FBO #0859
SOLICITATION NOTICE

B -- Follow-up to Stavanger Nested Case-Control Study

Notice Date

4/1/2004
 

Notice Type

Solicitation Notice
 

NAICS

541710 — Research and Development in the Physical, Engineering, and Life Sciences
 

Contracting Office

Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852
 

ZIP Code

20852
 

Solicitation Number

NCI-40052-NG
 

Response Due

4/16/2004
 

Archive Date

5/1/2004
 

Point of Contact

Malinda Holdcraft, Purchasing Agent, Phone (301) 402-4509, Fax (301) 402-4513, - Renita Smith, Contract Specialist, Phone 301-496-8612, Fax 301-480-0241,
 

E-Mail Address

holdcram@exchange.nih.gov, rs442i@nih.gov
 

Description

The National Cancer Institute (NCI), Basic Research Laboratory (BRL), Center for Cancer Research (CCR) plans to procure, on a sole source basis, record abstraction, data entry, and file development from the initial four months of the follow-up to the Stavanger Nested Case-Control Study of Preeclampsia with Norwegian University of Science and Technology, School of Medicine, NO-7489 Trondheim, Norway. The acquisition is being conducted under the simplified acquisition procedures authorized in FAR Part 13. The North American Industry Classification System Code is 541710 and the business size standard is 500 employees. Background: The Basic Research Laboratory, Center for Cancer Research, NCI, requires the data entry of and file development from the initial follow-up to the 1993 birth cohort of the study known as: The influence of preeclampsia on hormonal and anthropometric status in boys and girls at 10 and 13 years of age: Follow-up of the Stavanger population-based nested case-control study, (heretofore known as the Puberty Follow-Up Study). The ultimate purpose of this research project is to explore the biological mechanisms underlying why women who suffered from preeclampsia during pregnancy and their offspring are at significantly reduced risk of breast cancer (in mothers and daughters of that pregnancy) while the male offspring are at the lowest risk of prostate cancer identified in the literature. Information for the data file is obtained from anthropometric measurements, blood analysis, and pubertal assessment of the children when they were recently seen at the Rogaland Central Hospital, Stavanger Norway and from child and maternal questionnaires completed at the same time. Given the large sample size of 1,000 in the original birth study, there is the opportunity to have the statistical power to compute hormonal and other growth factor differences in the study population. Dr. Lars Vatten was the primary author to the research based in the Rogaland Hospital in Stavanger, Norway of the population-based study of women diagnosed with preeclampsia in pregnancy and their offspring and a comparable set of normotensive controls. His analysis of the original birth study identified significant growth retardation in newborns of preeclamptic in contrast with newborns of normotensive mothers as well as hormonal differences in the cord blood of the offspring of the two pregnancies. These hormones are associated with reduced risk of breast cancer in animal models and in human epidemiologic research. Dr. Vatten and his team therefore have the experience with the study cohort and have collaborated with the Rogaland Central Hospital to develop the file and link to other available registries in Norway. This is the only population-based study to date of preeclampsia and these women represent all women, who were diagnosed with preeclampsia in pregnancy in the birth years from 1993 through 1995 who resided in the Stavanger area in Norway. The NCI has the opportunity to conduct a follow-up of these mothers and children, linking with the original study database. The questionnaire items focus on dietary intake during the index pregnancy and since the birth of the index child, lifestyle and demographic characteristics, family history of cancer, and family history of reproductive disease, including preeclampsia in the mother's and biological father's families. Period of Performance: May 1, 2004 through September 30, 2004. The Norwegian University of Science and Technology, School of Medicine is the only known source to the NCI that can provide the aforementioned requirements. The Investigator has been involved in the original birth study and has worked for many years with the Medical Director of The Rogaland Central Hospital. Their insights from the original study as well as their scientific leadership in the area of preeclampsia provide extraordinary knowledge and experience in the Norwegian linked birth-cancer registry system, the public health record system, and in this particular study population. They have worked with the study data sets over the years and can thereby lead a team in the data analysis of the initial follow-up study. Therefore the background of the population, nature of its low risk for cancer, as well as the expertise and educational background of the Investigator and his team of data abstractors and analysts are all reasons for the sole source justification. This notice of intent is not a request for competitive quotation. However, if any interested party believes it can meet the above requirements, it may submit a statement of capabilities. The capability statement and any other furnished information must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can fully meet the requirements herein. Capability statements must be received in the contracting office by 1:00 PM EST on April 16, 2004. If you have any questions, please submit them in writing via electronic mail to Malinda Holdcraft, Purchasing Agent on holdcram@exchange.nih.gov or by fax 301-402-4513. A determination by the Government not to compete this proposed requirement based on responses to this notice is solely within the discretion of the Government. Information received shall be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. NCI-40052-NG.
 

Place of Performance

Address: NCI

Zip Code: 20892

Country: USA
 

Record

SN00558141-W 20040403/040401211830 (fbodaily.com)
 

Source

FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |